December 5, 2014

HUFFPOST

Edition: U.S. T

















HUFFPOST LIVE

Healthy Living • Health And Fitness • GPS for the Soul • Health News • Sleep • Healthy Living Videos • Moments Not Milestones • Lifestyle • Third Metric • Thrive





7 Of The Best Ab Exercises You're Probably Not Doing



Could Depression Be Caused By A Virus?




Immediately Responding To Work Email Is Actually Making You Worse At Your Job



FDA Approves First-Of-Its-Kind **Breast Cancer Drug**

AP | By MATTHEW PERRONE

Posted: 02/22/2013 12:30 pm EST | Updated: 02/18/2014 8:59 am EST



medication that targets tumor cells while sparing healthy ones.









The Food and Drug Administration has approved a first-of-a-kind breast cancer

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

Sponsored Links



LifeLock.com LifeLock® Data Breach Notifications Help

Protect Your Identity.



Stop Suffering From Nerve Pain Clinical studies find natural formula to be highly effective. Try it FREE*

ww.NeuropathyTreatmentGroup.com Odd Trick Fights Diabetes 'Unique" Proven Method To Control Blood

Sugar In 3 Weeks. Watch Video mart-Consumer-Lifestyles.com

Buy a link here

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had ADVERTISEMENT

FROM OUR PARTNERS



9 Surprising Signs of Depression



10 Foods Guaranteed To Help You Sleep Better



The Weird Sign You May Have Skin Cancer



The Simple Thing You Can Do In The Morning To Lose Weight

SUGGESTED FOR YOU

Why Burt Reynolds' Ex-Wife Is Getting Rid Of Everything He Gave Her



Genentech said Friday that Kadcyla will cost \$9,800 per month, compared to \$4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost \$94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drugbinding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a \$10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. rose 2 cents to \$14.32 in afternoon trading. The stock has ttraded in a 52-wek range of \$10.85 to \$18.10.

RELATED ON HUFFPOST:




MORE: Kadcyla Breast Cancer Drug, Kadcyla, Breast Cancer, New Breast Cancer Drug Approved, Breast Cancer Drug Approved, Breast Cancer Drug, Kadcyla Approved,



Jenna Bush Hager: 'I'm Fiercely Protective' Of Sasha And Malia Obama



'30 Rock' May Have Called Out Bill Cosby For Sexual Assault Back In 2009



These Striking Wedding Photos From Kenya Will Take Your Breath Away



Prince Harry Reveals Secret On World AIDS Day, Helps Fight Stigma



Reality Star Kristin Cavallari 'Felt Very, Very Used And Manipulated' By MTV



A Surprising Treatment For Depression That May Be Just As Effective As Talking To A Therapist



7 Brothers Give Bride The Wedding Gift To End All Wedding Gifts



You May Like

Promoted Links by Taboola



10 Secrets That Will Whiten Teeth



87 Yr Old Trainer **Shares Secret To Losing Weight**



8 Signs to Call It Quits on a Relationship



28 Celebs Who Have **Severe Illnesses**

PressroomVIP



ADHD Affects Adults: 5 'The Bachelorette' Star Signs WebMD



Josh Murray Is More Than 'Former Pro Bas...

ThePostGame

Around the Web

- Preast cancer: Treatments and drugs MayoClinic.com
- Drugs Approved for Breast Cancer National Cancer Institute
- F.D.A. Revokes Approval of Avastin for Use as Breast Cancer Drug ...
- Prug Approved for Breast Cancer WSJ.com
- What's new in breast cancer research and treatment?
- Preast Cancer Drug Approved CBS News Video
- FDA Gives Nod to New Breast Cancer Drug US News and World ...



WTF Is Jaggery, Anyway?



This Edible Holiday Gift Will Have **Everyone Raving**















The Morning Email Healthy Living

Get top stories and blog posts emailed to me each day.

Walgreens AT THE CORNER OF HAPPY & HEALTHY"



Advertise Log In Make HuffPost Your Home Page RSS Careers FAQ User Agreement | Privacy | Comment Policy | About Us | About Our Ads | Contact Us

Copyright ©2014 TheHuffingtonPost.com, Inc. | "The Huffington Post" is a registered trademark of TheHuffingtonPost.com, Inc. All rights reserved.

Part of AOL Lifestyle

